2021
Altered transcriptome and disease-related phenotype emerge only after fibroblasts harvested from patients with age-related macular degeneration are differentiated into retinal pigment epithelium
Cai H, Gong J, Team N, Noggle S, Paull D, Rizzolo LJ, Del Priore LV, Fields MA. Altered transcriptome and disease-related phenotype emerge only after fibroblasts harvested from patients with age-related macular degeneration are differentiated into retinal pigment epithelium. Experimental Eye Research 2021, 207: 108576. PMID: 33895162, DOI: 10.1016/j.exer.2021.108576.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationRetinal pigment epitheliumMacular degenerationPigment epitheliumInduced pluripotent stem cellsEtiology of AMDMitochondrial dysfunctionAge-matched controlsNovel therapeutic targetTranscriptome of fibroblastsAMD patientsNormal donorsFibroblasts of patientsTherapeutic targetPatientsMore studiesAltered transcriptomeDisease phenotypeSignificant differencesCell linesMitochondrial functionDysfunctionOriginal fibroblastsDistinct transcriptomesDegeneration
2016
Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)
Fields M, Cai H, Gong J, Del Priore L. Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD). Cells 2016, 5: 44. PMID: 27941641, PMCID: PMC5187528, DOI: 10.3390/cells5040044.Peer-Reviewed Original ResearchInduced pluripotent stem cellsEmbryonic stem cellsAge-related macular degenerationPluripotent stem cellsCell replacement therapyDisease modelingIPSC disease modelingStem cellsReplacement therapyMacular degenerationRegenerative medicineRetinal pigment epithelium cellsStem cell biologyPigment epithelium cellsRetinal degenerative disordersUnlimited sourceDrug development platformClinical trialsDevelopment platformStargardt diseaseAnimal modelsRetinal degenerationAutologous sourceDegenerative disordersTherapeutic use
2015
Chapter Twenty-Eight Retinoid Processing in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cultures
Fields MA, Bowrey HE, Gong J, Ablonczy Z, Del Priore LV. Chapter Twenty-Eight Retinoid Processing in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cultures. Progress In Nucleic Acid Research And Molecular Biology 2015, 134: 477-490. PMID: 26310172, PMCID: PMC8680204, DOI: 10.1016/bs.pmbts.2015.06.004.Peer-Reviewed Original ResearchConceptsRetinal pigment epitheliumRetinal degenerative diseasesAge-related macular degenerationDegenerative diseasesPluripotent stem cell (iPSC) technologyPromising clinical optionNative retinal pigment epitheliumRetinal degenerative disordersStem cell-derived retinal pigment epitheliumStem cell technologyVisual functionMacular degenerationPigment epitheliumRetinoid processingClinical optionDegenerative disordersClinical therapyCell therapyPluripotent stem cell-derived retinal pigment epitheliumVisual cycleRPE-specific proteinTherapyDiseaseStem cellsTrans retinol
2012
The Eye as a Target Organ for Stem Cell Therapy
Fields M, Hwang J, Gong J, Cai H, Del Priore L. The Eye as a Target Organ for Stem Cell Therapy. Stem Cell Biology And Regenerative Medicine 2012, 1-29. DOI: 10.1007/978-1-4614-5493-9_1.Peer-Reviewed Original ResearchAge-related macular degenerationRetinal pigment epitheliumRetinal degenerative diseasesStem cell therapyCell therapyRetinitis pigmentosaDegenerative diseasesCurrent clinical trialsPromising therapeutic optionNature of pathologyViable clinical optionReplacement therapyTherapeutic optionsClinical trialsCell replacement therapyMacular degenerationRetinal disordersCellular disarrayPigment epitheliumTarget organsPharmaceutical treatmentClinical optionProgressive cellular dysfunctionRetinal degenerationTherapeutic interventions